Diabetes Core Update cover image

Diabetes Core Update – May 2023

Diabetes Core Update

00:00

GLP1 Receptor Agonist and SGLT2 Inhibitors for Type 2 Diabetes

The study included a little over 1,300 participants and they estimated from that that 22.5 million United States adults who were diagnosed with type 2 diabetes would be 82%. Of those meeting the criteria, 3.7 used GLP1s, 5.3% used SGLT2s and a total for both combined is that 9% of the eligible individuals were actually being prescribed those medications.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app